Novo Nordisk reports earnings miss, sees profit and sales growth

Novo Nordisk (NVO) earnings came in lower than expected while reporting profits rose by 43 percent and sales are up by as much as 30 percent. Novo Nordisk is lifting its full-year outlook in accordance with the overwhelming success of its weight-loss and diabetes drugs while reducing their supply of lower doses.

Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down Novo Nordisk's earnings, also turning her attention to biotech company Illumina's (ILMN) slashed annual profits and the latest COVID-19 variant, "Eris", which the World Health Organization is calling a "variant of interest."